Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 <scp>POETYK PSO</scp>‐1, <scp>PSO</scp>‐2 and long‐term extension trials

April W. Armstrong, Mark Lebwohl, Richard B. Warren, Howard Sofen, Akimichi Morita, Carle Paul, Kim A. Papp, Matthew J. Colombo, Julie Scotto, John Vaile, Joe Zhuo, Eleni Vritzali, Victoria Berger, Georgene Schroeder, Subhashis Banerjee, Diamant Thaçi, Bruce Strober

Open source

DOI: 10.1111/jdv.20553
Published: 2025-03-06
Container: Journal of the European Academy of Dermatology and Venereology
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/jdv.20553,
  title = {Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 <scp>POETYK PSO</scp>‐1, <scp>PSO</scp>‐2 and long‐term extension trials},
  author = {April W. Armstrong and Mark Lebwohl and Richard B. Warren and Howard Sofen and Akimichi Morita and Carle Paul and Kim A. Papp and Matthew J. Colombo and Julie Scotto and John Vaile and Joe Zhuo and Eleni Vritzali and Victoria Berger and Georgene Schroeder and Subhashis Banerjee and Diamant Thaçi and Bruce Strober},
  year = {2025},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  doi = {10.1111/jdv.20553},
  url = {https://doi.org/10.1111/jdv.20553}
}

RIS

TY  - JOUR
TI  - Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 <scp>POETYK PSO</scp>‐1, <scp>PSO</scp>‐2 and long‐term extension trials
AU  - April W. Armstrong
AU  - Mark Lebwohl
AU  - Richard B. Warren
AU  - Howard Sofen
AU  - Akimichi Morita
AU  - Carle Paul
AU  - Kim A. Papp
AU  - Matthew J. Colombo
AU  - Julie Scotto
AU  - John Vaile
AU  - Joe Zhuo
AU  - Eleni Vritzali
AU  - Victoria Berger
AU  - Georgene Schroeder
AU  - Subhashis Banerjee
AU  - Diamant Thaçi
AU  - Bruce Strober
PY  - 2025
JO  - Journal of the European Academy of Dermatology and Venereology
DO  - 10.1111/jdv.20553
UR  - https://doi.org/10.1111/jdv.20553
ER  -

APA

Armstrong, A. W., Lebwohl, M., Warren, R. B., Sofen, H., Morita, A., Paul, C., Papp, K. A., Colombo, M. J., Scotto, J., Vaile, J., Zhuo, J., Vritzali, E., Berger, V., Schroeder, G., Banerjee, S., Thaçi, D., & Strober, B. (2025). Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 <scp>POETYK PSO</scp>‐1, <scp>PSO</scp>‐2 and long‐term extension trials. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20553

Source records

crossref · retrieved 2026-09-26T09:34:09.028Z